Sepset Biosciences is a leading diagnostic company specializing in the development of a revolutionary blood test called Sepset-ER. This test is designed to identify patients in the emergency room (ER) who are at high risk of developing severe sepsis and organ failure. With Sepset's test, doctors can obtain crucial and reliable data within just 1-2 hours, allowing them to select the most appropriate treatment for their patients at the right time.

Delaying treatment for sepsis by even just one hour increases the risk of death by 7. 6%. By providing early detection, Sepset's test aims to significantly improve patient survival rates and enhance the overall quality of care.

Moreover, Sepset's test has the added benefit of sparing patients who will not acquire sepsis from unnecessary antibiotic usage, thereby lowering the risk of antimicrobial resistance. Founded in 2016, Sepset Biosciences is the result of a collaboration between Dr. R.

E. W (Bob) Hancock and the Centre for Drug Research and Development/adMare. The company holds exclusive licenses to the patent-protected gene signature developed by Drs.

Hancock and Olga Pena, which accurately distinguishes between septic and non-septic patients and predicts organ failure. Sepset Biosciences is committed to increasing patient survival rates, improving healthcare efficiency, and advancing the field of sepsis diagnosis with its groundbreaking Sepset-ER blood test